13 terminated. 13 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Terminated 13 |
| Phase 1 | 1 | Terminated 1 |
Follow Chronic Hepatitis b: new trials by email Literature Review of Chronic Hepatitis b trials Research Report on Chronic Hepatitis b
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B STSG-0002 Injection - Chronic Hepatitis b | Phase 2 | Terminated | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 9 | 2023-04-25 | 2023-12-19 |
| To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B STSG-0002 Injection - Chronic Hepatitis b | Phase 2 | Terminated | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 9 | 2023-04-25 | 2023-12-19 |
| Treatment of Patients With Chronic Hepatitis B With Hepatitis B Immunoglobulins Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®) - Chronic Hepatitis B | Phase 2 | Terminated | Hannover Medical School | 13 | 2022-08-15 | 2025-09-04 |
| A Study of Safety and Efficacy of ATI-2173 and Vebicorvir in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection ATI-2173 25mg, Vebicorvir 300mg, Viread 300Mg Tablet - Chronic Hepatitis b | Phase 2 | Terminated | Antios Therapeutics, Inc | 2 | 2022-04-11 | 2022-05-31 |
| A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection VBR, AB-729, SOC NrtI - Chronic Hepatitis B | Phase 2 | Terminated | Assembly Biosciences | 65 | 2021-05-07 | 2023-11-14 |
| A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection ABI-H0731, ETV, Peg-IFNα - Chronic Hepatitis B | Phase 2 | Terminated | Assembly Biosciences | 54 | 2021-02-18 | 2023-10-06 |
| A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors ABI-H0731, Placebo, NrtI - Chronic Hepatitis B | Phase 2 | Terminated | Assembly Biosciences | 2 | 2020-11-11 | 2022-10-20 |
| A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection ABI-H2158, Placebo, Entecavir (ETV) - Chronic Hepatitis B | Phase 2 | Terminated | Assembly Biosciences | 88 | 2020-08-28 | 2022-09-15 |
| A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI) - Chronic Hepatitis B | Phase 2 | Terminated | Assembly Biosciences | 92 | 2018-12-20 | 2023-04-19 |
| Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB) Inarigivir Soproxil, TAF - Chronic Hepatitis B | Phase 2 | Terminated | Gilead Sciences | 123 | 2018-02-28 | 2022-04-04 |
| Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus ARC-520, Placebo, Entecavir - Chronic Hepatitis B | Phase 2 | Terminated | Arrowhead Pharmaceuticals | 4 | 2015-08-01 | 2025-11-03 |
| Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects albinterferon alfa-2b, Pegasys® - Chronic Hepatitis B | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 141 | 2009-07-01 | 2011-01-06 |
| Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B ACH126, 433 - Chronic Hepatitis B | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 85 | 2002-07-01 | 2021-02-18 |
Hepatitis B, Chronic (13) · Hepatitis B (5) · Bronchiolitis Obliterans Syndrome (1)
Blood-Borne Infections (13) · Chronic Disease (13) · Communicable Diseases (13) · DNA Virus Infections (13) · Digestive System Diseases (13) · Disease Attributes (13) · Hepadnaviridae Infections (13) · Hepatitis (13) · Hepatitis, Chronic (13) · Hepatitis, Viral, Human (13) · Infections (13) · Liver Diseases (13) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Virus Diseases (13)
entecavir (5) · Tenofovir (4) · tenofovir alafenamide (3) · ARC-520 (1) · Diphenhydramine (1) · Standard of Care (1) · Tablets (1) · albinterferon alfa-2b (1) · dexelvucitabine (1) · hepatitis B hyperimmune globulin (1) · peginterferon alfa-2a (1)
Assembly Biosciences (5) · Staidson (Beijing) Biopharmaceuticals Co., Ltd (2) · Alexion Pharmaceuticals, Inc. (1) · Antios Therapeutics, Inc (1) · Arrowhead Pharmaceuticals (1) · Gilead Sciences (1) · Hannover Medical School (1) · Novartis Pharmaceuticals (1)
China (6) · Hong Kong (5) · United States (5) · Canada (4) · New Zealand (4) · Australia (2) · South Korea (2) · Taiwan (2) · United Kingdom (2) · Bulgaria (1) · Germany (1) · Moldova (1) · Poland (1) · Thailand (1) · Ukraine (1)
Guiqiang Wang (2) · Grace Wang (1) · Grace Wang, MD (1) · Heiner Wedemeyer, Prof. (1) · M. F. Yuen, MD, PhD, DSc (1) · Michele Anderson (1) · Steven Knox (1)
PMID 24995515, PMID 34029994, PMID 38510983
2019 (1)